Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Finished Goods (2016 - 2018)

Vanda Pharmaceuticals (VNDA) has disclosed Finished Goods for 5 consecutive years, with $1.0 million as the latest value for Q1 2018.

  • Quarterly Finished Goods rose 31.98% to $1.0 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Mar 2018, up 31.98% year-over-year, with the annual reading at $760000.0 for FY2017, 0.26% changed from the prior year.
  • Finished Goods hit $1.0 million in Q1 2018 for Vanda Pharmaceuticals, up from $760000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.4 million in Q4 2014 to a low of $611000.0 in Q2 2017.
  • Historically, Finished Goods has averaged $1.5 million across 5 years, with a median of $941000.0 in 2014.
  • Biggest YoY gain for Finished Goods was 181.19% in 2015; the steepest drop was 61.87% in 2015.
  • Year by year, Finished Goods stood at $3.4 million in 2014, then tumbled by 61.87% to $1.3 million in 2015, then crashed by 41.11% to $762000.0 in 2016, then dropped by 0.26% to $760000.0 in 2017, then skyrocketed by 33.03% to $1.0 million in 2018.
  • Business Quant data shows Finished Goods for VNDA at $1.0 million in Q1 2018, $760000.0 in Q4 2017, and $858000.0 in Q3 2017.